Our reporters bring you news and highlights from BIO’s in-person and virtual events.
Patient advocacy organizations that leverage venture philanthropy—an approach to philanthropic giving that applies venture capital principles to achieve philanthropic goals—can provide vital funding sources […]
The BIG Summit meets at the intersection of patient advocacy and venture investment Read More »
We sometimes imagine the inventor of a patent as a lone vanguard leading the charge toward innovation, but in the era of team research
Who invented what? BIO IP panel tackles joint inventorship Read More »
Patents offer the intellectual property protections investors need to support biotech innovation. That’s why the Biotechnology Innovation Organization (BIO) annual IP Council and Committees
BIO 2025 IP Conference: Challenging times for the laws that drive innovation Read More »
At a time when the biopharma industry is seeking to increase U.S. manufacturing, Indiana is in the vanguard—and still expanding. During a Nov. 11
BIO on the American Road: Indiana, a production powerhouse, is still expanding Read More »
Venture capital funding for life sciences startups plummeted after legal changes weakened the patent system, according to new research that confirms the close relationship
Ahead of BIO IP Conference, research highlights why biotech needs strong patents Read More »
Three years after the passage of the Inflation Reduction Act (IRA), patient advocates and the biotech industry are working to navigate downstream negative impacts
PACE: Downstream effects of IRA on patients Read More »
Luke Rosen had hoped a new treatment would slow the progression of his daughter’s KIF1A Associated Neurological Disorder (KAND), but was amazed to see
PACE panel urges incentives for exciting new GTT drugs Read More »
The 340B program, in recent decades, has shown how the best laid plans can go sideways when not kept transparent and properly in check.
PACE: How 340B outgrew its goal and stopped helping patients Read More »
The FDA is hiring reviewers and finding ways to expedite drug approval, Dr. George Tidmarsh, Director of the Food and Drug Administration (FDA) Center
PACE: CDER director discusses faster approval, FDA morale with BIO CEO John F. Crowley Read More »
With Medicaid cuts expected, vaccine hesitancy getting politicized, and the continued challenge of Prescription Drug Affordability Boards (PDABs), state legislatures will drive many of
BIO PACE 2025: Patients need to ensure state policies enable access to medicine Read More »
